Healthpeak said it cited higher gains on property sales, higher Adjusted NOI from the Merger-acquired assets and other sources, and a lower loan loss reserve as the main drivers of the increase in net income applicable to common shares for the 3 months ended June 30, 2024. It said higher depreciation, interest expense and Merger-related costs partially offset these gains.

1. 01

   Healthpeak said it cited higher gains on property sales, higher Adjusted NOI from the Merger-acquired assets and other sources, and a lower loan loss reserve as the main drivers of the increase in net income applicable to common shares for the 3 months ended June 30, 2024. It said higher depreciation, interest expense and Merger-related costs partially offset these gains.

2. 02

   The company said net income applicable to common shares for the 6 months ended June 30, 2024 decreased mainly due to higher depreciation, Merger-related costs, interest expense, income tax expense and loan loss reserves. It attributed the income tax expense to the sale of a 65% interest in 2 lab buildings in San Diego, California in January 2024.

3. 03

   Healthpeak said its material cash requirements from debt as of June 30, 2024 increased by $1.7 billion to $8.6 billion compared with December 31, 2023. The company cited the $1.25 billion senior unsecured notes assumed in the Merger, the $750 million 2029 Term Loan, the $400 million 2028 Term Loan and $128 million of mortgage debt as the drivers. It said a decrease in commercial paper of $695 million partially offset the increase.

4. 04

   Healthpeak said net cash provided by operating activities for the 6 months ended June 30, 2024 decreased by $3 million from a year earlier, while net cash used in investing activities increased by $228 million. The company attributed the operating decrease to higher Merger-related costs and interest expense, and the investing change to factors including higher proceeds from property sales.

Key figures

Quarter ended June 30, 2024

Revenue

$696M

Net income

$146M

EPS

$0.21

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.